237 related articles for article (PubMed ID: 20129499)
21. Substance p.
Harrison S; Geppetti P
Int J Biochem Cell Biol; 2001 Jun; 33(6):555-76. PubMed ID: 11378438
[TBL] [Abstract][Full Text] [Related]
22. Recent developments in tachykinin NK1 receptor antagonists: prospects for the treatment of migraine headache.
Beattie DT; Connor HE; Hagan RM
Can J Physiol Pharmacol; 1995 Jul; 73(7):871-7. PubMed ID: 8846424
[TBL] [Abstract][Full Text] [Related]
23. Effects of neurokinin-1 receptor agonism and antagonism in the rostral ventromedial medulla of rats with acute or persistent inflammatory nociception.
Hamity MV; White SR; Hammond DL
Neuroscience; 2010 Feb; 165(3):902-13. PubMed ID: 19892001
[TBL] [Abstract][Full Text] [Related]
24. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
Adell A
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):113-21. PubMed ID: 15078186
[TBL] [Abstract][Full Text] [Related]
25. Distribution of Fos-like immunoreactivity in guinea-pig brain following administration of the neurokinin-1 receptor agonist, [SAR9,MET(O2)11]substance P.
Yip J; Chahl LA
Neuroscience; 1999; 94(2):663-73. PubMed ID: 10579226
[TBL] [Abstract][Full Text] [Related]
26. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
27. The promise of substance P inhibitors in fibromyalgia.
Russell IJ
Rheum Dis Clin North Am; 2002 May; 28(2):329-42. PubMed ID: 12122921
[TBL] [Abstract][Full Text] [Related]
28. Substance P and its Inhibition in Ocular Inflammation.
Bignami F; Rama P; Ferrari G
Curr Drug Targets; 2016; 17(11):1265-74. PubMed ID: 26477461
[TBL] [Abstract][Full Text] [Related]
29. Neuropeptide and kinin antagonists.
Hill RG; Oliver KR
Handb Exp Pharmacol; 2007; (177):181-216. PubMed ID: 17087124
[TBL] [Abstract][Full Text] [Related]
30. Substance P mediates reduced pneumonia rates after traumatic brain injury.
Yang S; Stepien D; Hanseman D; Robinson B; Goodman MD; Pritts TA; Caldwell CC; Remick DG; Lentsch AB
Crit Care Med; 2014 Sep; 42(9):2092-100. PubMed ID: 25014065
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the role of substance P in the growth of brain tumors.
Harford-Wright E; Lewis KM; Vink R; Ghabriel MN
Neuroscience; 2014 Mar; 261():85-94. PubMed ID: 24374326
[TBL] [Abstract][Full Text] [Related]
32. Differential SAR of quinuclidine SP antagonists between rat and human-type receptors.
Snider RM; Longo KP; Zorn SH; Morrone J; Jackson ER; Nagahisa A; Kanai Y; Suga O; Nakagaki M; Drozda SE
Regul Pept; 1993 Jul; 46(1-2):290-2. PubMed ID: 7692519
[No Abstract] [Full Text] [Related]
33. Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation.
Corrigan F; Mander KA; Leonard AV; Vink R
J Neuroinflammation; 2016 Oct; 13(1):264. PubMed ID: 27724914
[TBL] [Abstract][Full Text] [Related]
34. Substance P: a pioneer amongst neuropeptides.
Hökfelt T; Pernow B; Wahren J
J Intern Med; 2001 Jan; 249(1):27-40. PubMed ID: 11168782
[TBL] [Abstract][Full Text] [Related]
35. A flexible approach to the design of new potent substance P receptor ligands.
Millet R; Goossens L; Bertrand-Caumont K; Goossens JF; Houssin R; Hénichart JP
J Pharm Pharmacol; 2001 Jul; 53(7):929-34. PubMed ID: 11480541
[TBL] [Abstract][Full Text] [Related]
36. Crosstalk between neurokinin receptor signaling and neuroinflammation in neurological disorders.
Eapen PM; Rao CM; Nampoothiri M
Rev Neurosci; 2019 Apr; 30(3):233-243. PubMed ID: 30260793
[TBL] [Abstract][Full Text] [Related]
37. Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury.
Thornton E; Ziebell JM; Leonard AV; Vink R
Molecules; 2010 Sep; 15(9):6598-618. PubMed ID: 20877247
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of substance P transport across the blood-brain barrier.
Chappa AK; Audus KL; Lunte SM
Pharm Res; 2006 Jun; 23(6):1201-8. PubMed ID: 16729222
[TBL] [Abstract][Full Text] [Related]
39. Possible involvement of neurokinin receptors in CNS and neuromuscular synapse in the realization of the effects of CAPAH and substance P.
Semina II; Bukharaeva EA; Shilovskaya EV; Baichurina AZ; Garaev RS
Bull Exp Biol Med; 2002 Sep; 134(3):267-70. PubMed ID: 12511999
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke.
Turner R; Vink R
Drug News Perspect; 2007 May; 20(4):221-6. PubMed ID: 17637934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
